Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories.


Journal

Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828

Informations de publication

Date de publication:
09 2022
Historique:
pubmed: 2 9 2022
medline: 28 9 2022
entrez: 1 9 2022
Statut: ppublish

Résumé

Drugs used to treat psychotic disorders ('antipsychotics') have been widely used in psychiatry since the introduction of chlorpromazine in the mid-1950s. The categorization of these drugs evolved in a piecemeal way, relying initially on grouping by chemical structure (e.g. phenothiazines, butyrophenones), then by epoch of introduction (e.g. first generation ('conventional') vs second generation ('atypical')). As psychopharmacological expertise has advanced, it has become possible to quantify affinities for each drug in this class for relevant receptors including dopamine D2, 5HT2A, 5HT2C, histamine H1 and others. However, until the recent emergence of a new generation of agents known collectively as dopamine D2 receptor partial agonists (e.g. aripiprazole, brexpiprazole and cariprazine), there had been little reference in drug classification to specific pharmacological properties. An overview of data on receptor affinities across multiple drugs and receptor types would permit categorization according to binding affinities and putative pharmacological mechanisms. In this paper, we have attempted to construct a 'subway map' of 32 drugs used for treatment of psychotic disorders. This design allows a visualization of both the historical classifications by structure and epoch of introduction, and of the binding affinities for key receptors based on appraisal of scientific literature. The map represents a step towards categorization by mechanism, allowing prescribers and patients to understand which drugs share common biological features and the extent to which drugs may have similarities and differences in their mechanisms. In addition, this approach may encourage more logical groupings of drugs to be used in systematic reviews and meta-analyses.

Identifiants

pubmed: 36045588
doi: 10.1177/02698811221115758
pmc: PMC9516596
doi:

Substances chimiques

Antipsychotic Agents 0
Butyrophenones 0
Dopamine Agonists 0
Receptors, Dopamine D2 0
Histamine 820484N8I3
Aripiprazole 82VFR53I78
Chlorpromazine U42B7VYA4P
Dopamine VTD58H1Z2X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1007-1015

Références

Pharmacol Res. 1999 Aug;40(2):165-70
pubmed: 10433876
Expert Opin Drug Saf. 2016 Sep;15(9):1193-203
pubmed: 27207070
Pharmacol Ther. 1995 May;66(2):339-68
pubmed: 7667401
Innov Clin Neurosci. 2018 Feb 1;15(1-2):16-22
pubmed: 29497575
Pharmacol Ther. 2018 Dec;192:20-41
pubmed: 29953902
Science. 1975 Jun 20;188(4194):1217-9
pubmed: 1145194
Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12
pubmed: 27525990
J Pharmacol Exp Ther. 2014 Sep;350(3):589-604
pubmed: 24947465
Neuropsychiatr Dis Treat. 2013;9:587-94
pubmed: 23766647
J Pharmacol Exp Ther. 2010 Jul;334(1):171-81
pubmed: 20404009
Life Sci. 1984 Apr 16;34(16):1529-40
pubmed: 6144029
Front Neurosci. 2019 Dec 06;13:1309
pubmed: 31866817
J Psychopharmacol. 2009 Jun;23(4):343-5
pubmed: 19433474
Neuropharmacology. 2018 Jul 1;136(Pt C):438-448
pubmed: 28893562
Eur Neuropsychopharmacol. 2014 Jul;24(7):1005-14
pubmed: 24630385
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1145-58
pubmed: 14642973

Auteurs

Crystal Zhou (C)

Geriatric Psychiatry Division, Centre for Addiction and Mental Health/University of Toronto, Toronto, ON, Canada.
Geriatric Psychiatry Division, Vancouver Island Health Authority, Victoria, BC, Canada.

David J Nutt (DJ)

Neuropsychopharmacology Unit, Division of Brain Sciences, Imperial College London, London, UK.

Simon Jc Davies (SJ)

Geriatric Psychiatry Division, Centre for Addiction and Mental Health/University of Toronto, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH